Literature DB >> 12691830

Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma.

Jerry Jaboin1, Audrey Hong, Chong Jai Kim, Carol J Thiele.   

Abstract

We evaluated the ability of brain-derived neurotrophic factor (BDNF) to decrease the chemosensitivity of neuroblastoma cells to cisplatin. Two cell lines, one derived from SH-SY5Y (SY5Y-TB8) and the other from SK-N-AS (AS-TB8), transfected with a TrkB plasmid were generated, and used to assess the effects of activation of the TrkB signal transduction path on cisplatin (Cis) induced apoptosis. BDNF treatment of each of the TrkB expressing cells blocked cisplatin-induced cell death. BDNF's ability to rescue the cells from cisplatin-induced cell death was inhibited by treatment with the Trk tyrosine kinase inhibitor, K252a, and the phosphatidylinositol 3'-kinase (PI)-3-kinase inhibitor, LY294002. This indicates that the activation of the TrkB path through PI-3-kinase is required for BDNF's survival-promoting effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691830     DOI: 10.1016/s0304-3835(02)00723-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

2.  TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells.

Authors:  Siyang Zhang; Dawei Guo; Wenting Luo; Qingfu Zhang; Ying Zhang; Chunyan Li; Yao Lu; Zeshi Cui; Xueshan Qiu
Journal:  BMC Cancer       Date:  2010-02-16       Impact factor: 4.430

3.  The effect of brain-derived neurotrophic factor on angiogenesis.

Authors:  Chunyan Sun; Yu Hu; Zhangbo Chu; Jing Huang; Lu Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

4.  HBZ stimulates brain-derived neurotrophic factor/TrkB autocrine/paracrine signaling to promote survival of human T-cell leukemia virus type 1-Infected T cells.

Authors:  Nicholas Polakowski; Marie Terol; Kimson Hoang; Isabelle Nash; Sylvain Laverdure; Hélène Gazon; Gilda Belrose; Jean-Michel Mesnard; Raymond Césaire; Jean-Marie Péloponèse; Isabelle Lemasson
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

5.  Low-doses of cisplatin injure hippocampal synapses: a mechanism for 'chemo' brain?

Authors:  Adrienne L Andres; Xing Gong; Kaijun Di; Daniela A Bota
Journal:  Exp Neurol       Date:  2014-03-02       Impact factor: 5.330

Review 6.  The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers.

Authors:  David S Shulman; Steven G DuBois
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 7.  Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology.

Authors:  Jason Tilan; Joanna Kitlinska
Journal:  Neuropeptides       Date:  2015-10-26       Impact factor: 3.286

8.  Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients.

Authors:  Diana C Pearre; Daniela A Bota
Journal:  Expert Rev Qual Life Cancer Care       Date:  2018-02-26

9.  MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.

Authors:  J Ryan; A Tivnan; J Fay; K Bryan; M Meehan; L Creevey; J Lynch; I M Bray; A O'Meara; L Tracey; A M Davidoff; R L Stallings
Journal:  Br J Cancer       Date:  2012-08-14       Impact factor: 7.640

10.  Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.

Authors:  M Czarnecka; E Trinh; C Lu; A Kuan-Celarier; S Galli; S-H Hong; J U Tilan; N Talisman; E Izycka-Swieszewska; J Tsuei; C Yang; S Martin; M Horton; D Christian; L Everhart; I Maheswaran; J Kitlinska
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.